Israeli blood testing startup S.D. Sight Diagnostics Ltd. has raised $71 million from international venture capital funds and U.S. corporations, Clal Biotechnology Industries Ltd. revealed in a report sent to the Tel Aviv Stock Exchange last week. Sight Diagnostics has yet to announce the details of the new funding round, but Clal Biotechnology Industries stated in its report that following the news its Anatomy Technology Fund, of which it holds a 50% stake, now owns 4% of Sight Diagnostics.

Read more here.